Oncology Drugs Advisory Committee (ODAC)

The Oncology Drugs Advisory Committee (ODAC) is a group of experts that provides independent advice to the U.S. Food and Drug Administration (FDA) regarding the safety and effectiveness of cancer treatments. They review clinical data, assess benefits and risks, and help ensure that new cancer drugs are safe for patients and perform as expected. ODAC’s recommendations guide the FDA in making informed decisions about whether to approve, modify, or reject cancer medications, ultimately aiming to improve patient care and public health.